GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twenty research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $9.32.
Several analysts have commented on the stock. Wells Fargo & Company upgraded shares of GoodRx from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $7.50 to $10.00 in a report on Monday, March 25th. Barclays upped their price target on GoodRx from $9.00 to $10.00 and gave the stock an “overweight” rating in a research note on Monday, May 20th. Raymond James raised GoodRx from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research report on Thursday, May 16th. KeyCorp upgraded shares of GoodRx from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a report on Wednesday, April 10th. Finally, Morgan Stanley increased their price target on shares of GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research note on Monday, June 10th.
Check Out Our Latest Research Report on GoodRx
Institutional Trading of GoodRx
GoodRx Price Performance
GDRX opened at $7.80 on Friday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29. The stock has a market capitalization of $2.93 billion, a PE ratio of -779.22, a price-to-earnings-growth ratio of 3.58 and a beta of 1.40. The stock’s 50 day moving average price is $7.61 and its 200-day moving average price is $6.96. GoodRx has a 52-week low of $4.14 and a 52-week high of $9.37.
GoodRx (NASDAQ:GDRX – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The company had revenue of $197.88 million for the quarter, compared to analysts’ expectations of $196.20 million. GoodRx had a negative net margin of 0.86% and a positive return on equity of 3.45%. On average, equities research analysts predict that GoodRx will post 0.17 EPS for the current year.
About GoodRx
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Recommended Stories
- Five stocks we like better than GoodRx
- What Do S&P 500 Stocks Tell Investors About the Market?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- The 3 Best Blue-Chip Stocks to Buy Now
- MarketBeat Week in Review – 6/24 – 6/28
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.